GlassScriptPhysician profile
Kayla Williamson
NPI 1982076923
$9,619.47
in general payments reported to CMS, 2019-2025
35 companies · $3,097 in 2025
The $3,097 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $823 · 2022: $1,950 · 2023: $1,932 · 2024: $1,818 · 2025: $3,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,456 · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,456.12 |
| Education | $390.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,324.70 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,563.87 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $616.21 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $603.78 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $519.09 | 2021-2025 | Ofev, Jascayd |
| Harmony Biosciences LLC | $467.80 | 2022-2025 | Wakix |
| Genentech USA, INC. | $442.45 | 2022-2025 | Xolair |
| Mylan Specialty L.P. | $418.31 | 2021-2024 | Yupelri |
| Verona Pharma, INC. | $318.29 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $224.69 | 2022-2025 | Opsumit, Opsynvi |
| Amgen INC. | $222.42 | 2022-2025 | Tezspire |
| Insmed, INC. | $211.14 | 2023-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $188.83 | 2021-2025 | Glassia |
| Axsome Therapeutics, INC. | $177.83 | 2023-2025 | Sunosi |
| Grifols USA, LLC | $155.27 | 2021-2025 | Prolastin-C Liquid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $135.13 | 2024 | |
| Inogen, INC. | $103.17 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $100.90 | 2021-2023 | |
| Viatris Specialty LLC | $99.44 | 2025 | Yupelri |
| United Therapeutics Corporation | $96.14 | 2023-2025 | Tyvaso, Tyvaso |
| Pfizer INC. | $83.98 | 2024-2025 | |
| Abbvie INC. | $83.40 | 2021-2022 | |
| Baxter Healthcare | $68.30 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Novo Nordisk INC | $48.90 | 2021 | |
| 3b Medical, INC. | $48.21 | 2025 | Luna |
| Philips North America LLC | $46.71 | 2022-2023 | |
| Lilly USA, LLC | $44.05 | 2025 | Zepbound |
| Avadel Cns Pharmaceuticals, LLC | $38.90 | 2025 | Lumryz |
| Merck Sharp & Dohme LLC | $36.93 | 2023-2025 | Winrevair |
| Electromed, INC. | $29.32 | 2025 | Smartvest |
| Melinta Therapeutics, LLC | $23.24 | 2024 | Kimyrsa, Rezzayo |
| Abbott Laboratories | $23.12 | 2022 | |
| Inspire Medical Systems, INC. | $21.19 | 2023 | Inspire |
| Mallinckrodt Hospital Products INC. | $18.03 | 2025 | Terlivaz |
| Janssen Pharmaceuticals, INC | $15.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.